Actualités
Séminaires

Jeudi 26 novembre 14H, séminaire IRCM Reporté à une date ultérieure


Gergely Szakacs

Institute of Cancer Research, Medical University of Vienna, Austria

“Targeting efflux transporters in multidrug resistant cancer: an unfinished business”

Clinical evidence shows that, following initial response to treatment, drug-resistant cancer cells frequently evolve, and eventually most tumors become resistant to all available therapies. The most straightforward cause of therapy resistance is linked to cellular alterations that prevent drugs to act on their target. Upregulation of cell membrane efflux transporters of the ATP-binding cassette (ABC) superfamily leads to simultaneous resistance against structurally and functionally unrelated chemotherapeutic agents. In particular, P-glycoprotein (Pgp, MDR1), the product of ABCB1 gene, was shown to be expressed in several drug resistant malignancies. Based on the correlation of P-glycoprotein expression and function with unfavorable treatment response, it is universally accepted that pharmacological modulation of the MDR phenotype has the potential to significantly increase the efficacy of currently available anticancer therapies. Unfortunately, despite a few early successes, clinical trials conducted with Pgp inhibitors did not fulfill this expectation, failing to confirm clinical benefit. Failure of the trials led to a setback in research, and the shutdown of the pharmaceutical development of transporter inhibitors for the improvement of anticancer therapy. Yet the “transporter problem” has not vanished, as evidenced by new studies supporting the relevance and benefit of research on the role of ABC transporters in clinical drug resistance. Failure of the inhibitors has boosted research in other directions, exploring the possibility to evade efflux, or to exploit the paradoxical sensitivity associated with efflux-based drug resistance mechanisms. In this talk I will describe new approaches to combating multidrug-resistant cancer, including the development of drugs that engage, evade or exploit efflux by P-glycoprotein.

Contact : Charles Theillet at inserm


Mercredi 21 octobre à 14h, sÉminaire ircm


Silvia Fre

Institut Curie, Paris

“Cell heterogeneity in colon cancer: how do cells communicate within a tumor?"

Contact : Julie Pannequin (IGF)


Vendredi 20 novembre à 11h, sÉminaire ircm


Nathalie Mazure

Centre Méditerranéen de Médecine Moléculaire (C3M), Université Nice Sophia Antipolis

“Identification of a new aggressive axis driven by ciliogenesis and absence of VDAC1-ΔC in clear cell Renal Cell Carcinoma patients"

Contact IRCM : Cathy Tessier


Mardi 16 Juin à 16H e-séminaire ircm


Alexandra Garancher

Sanford Burnham Prebys Medical Discovery Institute, San Diego, Ca. USA

“Elucidating pediatric brain tumor immunology to overcome immune evasion and to improve immunotherapy“

NB: les conditions de diffusion seront précisées ultérieurement et dépendront de la qualité de la transmission lors de tests qui doivent être effectués prochainement

 


Lundi 09 Mars 2020 à 14h00
seminaire IRCM


Pierre-Francois Roux

Johnson and Johnson and Institut Pasteur, Paris

"Towards a Systems View of the Senescence Cell Fate »

Contact IRCM : Laurent Le Cam


Mercredi 04 Mars 2020 à 11h00
séminaire mabimprove


Céline LENGELLE-KARIBAYE – Annie-Pierre JOINVILLE-BERA

Service de Pharmacosurveillance - Centre Régional de Pharmacovigilance et d'Information sur le Médicament Centre Val de Loire - Unité de Vigilance des recherches biomédicales CHRU Tours

“When interleukin 17 inhibition explain unexpected adverse effects and change safety profile of sécukinumab”

Contact Université de tours : Hervé Watier


Mercredi 19 Février 2020 à 11h00
seminaire IRCM


Hussein Issaoui

CRIBL UMR CNRS 7276 INSERM 1262, Limoges

“The role of the transcriptional activators of the immunoglobulin heavy chain locus in the normal and pathological development of B lympocytes“

Contact IRCM : Antonio Maraver


Mercredi 05 Février 2020 à 11h00
seminaire mabimprove


Valérie Attuil-Audenis

Ph.D, Responsable département produits, Mablink Bioscience

“Highly-loaded hydrophilic ADC drug linker platform”

Contact IRCM : Thierry Chardès



© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés